Patents Assigned to Infinity Pharmaceuticals, Inc.
  • Triazoles as inhibitors of fatty acid synthase
    Patent number: 8450350
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: May 28, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Thomas T. Tibbitts
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20130131063
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: May 23, 2013
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20130059819
    Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: March 7, 2013
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventor: INFINITY PHARMACEUTICALS, INC.
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20130053362
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
    Type: Application
    Filed: July 18, 2012
    Publication date: February 28, 2013
    Applicants: INTELLKINE, LLC, INFINITY PHARMACEUTICALS, INC.
    Inventors: Alfredo C. CASTRO, Catherine A. EVANS, Somarajannair JANARDANANNAIR, Andre LESCARBEAU, Tao LIU, Daniel A. SNYDER, Martin R. TREMBLAY, Pingda REN, Yi LIU, Liansheng LI, Katrina CHAN
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20130029984
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: July 18, 2012
    Publication date: January 31, 2013
    Applicants: INTELLIKINE, LLC, INFINITY PHARMACEUTICALS, INC.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Andre Lescarbeau, Tao Liu, Daniel A. Snyder, Martin R. Tremblay, Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20130029982
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: July 18, 2012
    Publication date: January 31, 2013
    Applicants: INTELLIKINE, LLC, INFINITY PHARMACEUTICALS, INC.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Daniel A. Snyder, Martin R. Tremblay, Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan
  • Inhibitors of fatty acid amide hydrolase
    Patent number: 8349814
    Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: January 8, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
  • Inhibitors of fatty acid amide hydrolase
    Patent number: 8329675
    Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: December 11, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
  • Ansamycin formulations and methods of use thereof
    Patent number: 8283343
    Abstract: Amorphous, polymorphic, and solvated forms of 17-amino geldanamycin are disclosed. These compounds are particularly useful for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: October 9, 2012
    Assignee: Infinity Pharmaceuticals Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 8252779
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: August 28, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • Cyclopamine analogues and methods of use thereof
    Patent number: 8236956
    Abstract: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: August 7, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Alfredo C. Castro, Michael A. Foley, Somarajan Nair Janardanan Nair, Marta Nevalainen, James R. Porter, Martin R. Tremblay
  • Methods of use of cyclopamine analogs
    Patent number: 8227509
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: July 24, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, William Matsui, Karen J. McGovern, Martin R. Tremblay
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8178690
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 15, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • ANTI-FATTY ACID AMIDE HYDROLASE-2 ANTIBODIES AND USES THEREOF
    Publication number: 20120115162
    Abstract: Antibodies that specifically bind to fatty acid amide hydrolases and methods of using the antibodies are provided herein.
    Type: Application
    Filed: April 22, 2010
    Publication date: May 10, 2012
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Janid A. Ali, James Brownell, Erin Brophy, Thomas T. Tibbitts
  • Methods Of Treating Liposarcoma
    Publication number: 20120108563
    Abstract: Provided herein are methods of treating liposarcoma in a subject, the method comprising administering to the subject a therapeutically effective amount of an Hsp90 inhibitor.
    Type: Application
    Filed: May 19, 2010
    Publication date: May 3, 2012
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventor: David S. Grayzel
  • INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20120088738
    Abstract: Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2, R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating an FAAH-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.
    Type: Application
    Filed: April 7, 2010
    Publication date: April 12, 2012
    Applicant: INFINITY PHARMACEUTICALS ,INC
    Inventors: Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael L. Grogan
  • Enzymatic Transamination of Cyclopamine Analogs
    Publication number: 20120083607
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: July 1, 2011
    Publication date: April 5, 2012
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Brian c. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Charles W. Johannes, Gregg F. Keaney, Priscilla L. White, Sheldon L. Wallerstein
  • Transfer Hydrogenation of Cyclopamine Analogs
    Publication number: 20120065400
    Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
  • Transfer Hydrogenation of Cyclopamine Analogs
    Publication number: 20120065399
    Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
  • Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof
    Publication number: 20120058982
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Application
    Filed: July 27, 2011
    Publication date: March 8, 2012
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright